Market Overview

NuVasive Announces First Patient in Japan Treated with XLIF(R) Technique

Share:
Related NUVA
Piper Jaffray Met With NuVasive Management And Came Away 'Still Confident'
Goldman Sachs' New Pair Trade? Bull Zeltiq Aesthetics, Bear NuVasive
Masimo SpHb System Gets Picked by Cancer Center in Brazil (Zacks)

NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is proud to announce that the very first eXtreme Lateral Interbody Fusion (XLIF(R)) procedures were performed yesterday and today at two different hospitals in Japan. NuVasive has received regulatory Shonin approval for several products to offer the XLIF surgical technique as a minimally invasive option for lumbar spine fusion to patients and surgeons in Japan. The approval furthers the Company's ability to participate in the Japanese market, adding the XLIF approach to the cervical and posterior products that were approved for use late last year.

Posted-In: News

 

Related Articles (NUVA)

View Comments and Join the Discussion!

Get Benzinga's Newsletters